Necrotizing myopathies: Beyond statins

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 679-683

  Mammen, Andrew L ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Anti HMG CoA reductase; Autoimmune; Muscle; Myopathy; Myositis; Necrotizing; Signal recognition particle; Statin

Indexed keywords

AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; SIGNAL RECOGNITION PARTICLE;

ANTISYNTHETASE SYNDROME; AUTOIMMUNE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MUSCLE BIOPSY; MUSCLE NECROSIS; MYOPATHY; MYOSITIS; NECROTIZING MYOPATHY; PRIORITY JOURNAL; REVIEW; SCLERODERMA ASSOCIATED MYOPATHY; IMMUNOLOGY; MUSCLE DISEASE; PATHOLOGY; SKELETAL MUSCLE;

AUTOIMMUNE DISEASES; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 84927759355     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000106     Document Type: Review

References (25)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344-347.
2. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325:1487-1498.
3. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16:193-208.
4. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403-407.
5. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003. Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337-345.
6. Preuße C, Goebel HH, Held J, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 2012; 181:2161-2171.
7. Reichlin M, Mattioli M. Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 1976; 5:12-20.
8. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23:881-888.
9. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 1986; 83:9507-9511.
10. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420-428.
11. Kao AH, Lacomis D, Lucas M, et al. Antisignal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-215.
12. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Antisignal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635-1638.
13. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757-2766.
14. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185-190.
15. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713-721.
16. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64:269-272.
17. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93:150-157.
18. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductaseassociated autoimmune myopathy. Arthritis Rheum 2012; 64:4087-4093.
19. Mehndiratta P, Mehta S, Manjila SV, et al. Isolated necrotizing myopathy associated with ANTI-PL12 antibody. Muscle Nerve 2012; 46:282-286.
20. Meyer A, Messer L, Goetz J, et al. Immune-mediated necrotizing myopathies are serologically heterogeneous and autoantibodies may predict their clinical phenotype: two cases associated with anti-Pl7 antibodies. Scand J Rheumatol 2014; 43:81-83.
21. Bhansing KJ, Lammens M, Knaapen HK, et al. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Res Ther 2014; 16:R111. [Epub ahead of print]
22. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328-1334.
23. Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97:2905-2910.
24. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664-678.
25. Benveniste O, Drouot L, Jouen F, et al. Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:1961-1971.